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 1. Summary  
Comparison of treatment options of uveitis in juvenile idiopathic arthritis  
Nataša Basrak  
 
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatologic disease 
in children and it affects approximately 1 in 1000 children worldwide. Children with 
JIA have an increased risk for uveitis and as many as 10-30% of children with JIA 
will develop uveitis. Severe or untreated uveitis can lead to long term complications 
and consequences, including cataracts, glaucoma and blindness; therefore 
treatment is of utmost importance. Topical corticosteroids and systemic 
immunosuppressants have been treatment of choice, however recently biologic 
agents have been used. An exploration of numerous clinical trials concerning the 
treatment of uveitis in JIA patients is necessary to conclude what the newest gold 
standard treatment should be. Specifically, a comparison of immunosuppressants 
alone versus a combination with biologic agents should be explored to deduce which 
is the most beneficial for treatment and if there is a difference in extent or type of 
side effects. Considering the high incidence level of this illness and the potential 
consequences if treatment is not provided, there is great importance in reviewing 
multiple clinical trials and concluding what the current treatment algorithm should be. 
This review aims to explore the current medical treatment of JIA –associated uveitis 
and the effectiveness and safety of the drugs involved.  
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 2. Sažetak 
Komparacija načina liječenja uveitisa u juvenilnom idiopatskom artritisu  
Nataša Basrak  
 
Juvenilni idiopatski artritis (JIA) najčešća je kronična reumatološka bolest kod djece i 
javlja se otprilike kod 1 od 1000 djece diljem svijeta. Djeca s JIA imaju povećani rizik 
za uveitis i čak 10-30% djece s JIA-om će razviti uveitis. Teški oblik uveitisa ili 
neliječeni uveitis može dovesti do dugoročnih komplikacija i posljedica, uključujući 
kataraktu, glaukom i sljepoću; Stoga je liječenje od najveće važnosti. Topički 
primjenjeni kortikosteroidi i sustavni imunosupresivi lijekovi su izbora, no u posljednje 
vrijeme koriste se biološki lijekovi. Analizom brojnih kliničkih ispitivanja vezanih uz 
liječenje uveitisa u pacijenata s JIA-om potrebno je zaključiti koji bi bio najnoviji 
standard u liječenju ove bolesti. Posebno, treba usporediti uporabu imunosupresiva 
samih u odnosu na kombinaciju s biološkim lijekovima kako bi se utvrdio koji je lijek 
najkorisniji za liječenje i utvrditi razliku u opsegu i vrsti nuspojava. S obzirom na 
visoku incidenciju ove bolesti i potencijalne posljedice neliječene bolesti, velika je 
važnost u analizi višestrukih kliničkih ispitivanja i zaključivanju što bi trebao biti 
trenutni algoritm liječenja.  Cilj ovog preglednog rada je istražiti suvremeno liječenje 




Ključne riječi: Uveitis, JIA
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3. Juvenile Idiopathic Arthritis 
 
 Juvenile idiopathic arthritis (JIA), formerly juvenile rheumatoid arthritis 
(JRA) has several subtypes, in which there are varying numbers of joints 
involved, types of joints, systemic features, eye disease and association with 
human leukocyte antigens to name a few. The most common types are 
oligoarticular (<5 joints are involved) and polyarticular (≥5 joints are involved), 
which account in total about 90% of all patients with JIA (1).  
 The etiology is unknown and common characteristics of the illness 
include chronic synovitis, in which the synovium thickens and becomes 
hypervascularized and infiltrated with lymphocytes and inflammatory 
cytokines (1). There is also vascular endothelial hyperplasia and continuous 
erosion of articular cartilage and eventually, even the bony structures, due to 
the inflammation. Clinical features are often morning stiffness, fatigue, joint 
pain in later parts of the day, joint swelling, decreased motion, however no 
redness (1).  
 Regardless of the type of JIA, all the children are at risk for ocular 
issues, mainly chronic iridocyclitis or uveitis. There is an association between 
HLA-DR5, HLA-DR6, and HLA-DR8 and uveitis (1). Additionally, children with 
positive antinuclear antibody are at an even higher risk for chronic uveitis (1). 
A young female with oligoarticular JIA and positive antinuclear antibody has 
the highest risk of uveitis with an incidence of 80%.  
 Treatment of JIA focuses on decreasing inflammation and deformity, 
increasing mobility and preventing blindness. First choice is nonsteroidal anti-
inflammatory drugs (NSAIDs). If treatment is not sufficient, second line 
medications such as hydroxychloroquine and sulfasalazine may be used. 
Biologic agents have also been used and include agents that inhibit TNF-
alpha, including etanercept (ETN), infliximab and adalimumab (ADA). 
However, the side effects of these drugs are greater and include serious 
infection and possibly malignancy (1). Standard treatment of JIA consists of 
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NSAIDs, systemic glucocorticoids and/or disease- modifying antirheumatic 
drugs (DMARDs) such as methotrexate (MTX), however 30% fail to respond 
to treatment (2). Current US guidelines recommend “switching to biologic 
therapy in JIA patients with persistent moderate-to-severe disease activity, or 
drug intolerance, after four months of treatment with standard medical 
therapy” (3). 
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4. Uveitis  
 
 Uveitis is uveal inflammation that may involve one or all parts of the 
tract, including anterior uveitis (iritis), intermediate uveitis and posterior 
uveitis. JIA is primarily associated with anterior uveitis (4). The etiology is 
autoimmune with “predominant involvement of CD4+ T cells” (5). In 
oligoarticular JIA patients, chronic anterior uveitis has been particularly 
associated with HLA-DRB1*1104 and HLA-DPB1*0201 alleles (5). They are 
linked with a 7.7 times increased risk of chronic uveitis (5). While, HLA-DR1 
has been proven to be protective (6). 
 Uveitis associated with JIA can be discovered at various points of the 
disease process. It can be asymptomatic until visual loss, thus regular 
ophthalmologic check-ups are necessary to allow prompt treatment. It is 
important to use a slit-lamp examination to look for anterior chamber 
inflammation. If diagnosed prior to visual loss, there are multiple clinical 
features. They can include photophobia, ocular pain, globe tenderness, brow 
ache, lacrimation, and/or ciliary flush (4). However, considering that the 
patients are juvenile, they may not report symptoms until vision loss is 
experienced.  
 Approximately 12-38% of JIA patients develop uveitis within seven 
years of disease onset, while 30-50% have structural complications present at 
diagnosis (7). Treatment should be aimed at decreasing “inflammatory 
activity, complications and risk factors for losing visual acuity” (8). 
 
(A) Diagnosis of Uveitis 
 
 Children with JIA-associated chronic anterior uveitis are mostly 
asymptomatic thus routine ophthalmologic screening is prudent or else 
patients will present with serious complications. A predictor of visual outcome 
is the ocular condition during the first visit. Also, uveitis onset before or right 
after arthritis is a poor predictor of visual outcome.  
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 Uveitis associated with JIA is usually bilateral, nongranulomatous and 
has a chronic relapsing course, but granulomatous disease does not exclude 
the diagnosis (9). “The most common complications include band 
keratopathy, cataract, posterior synechiae, glaucoma, maculopathy, hypotony 
and amblyopia” (9). Past cohort studies have found that rate of blindness can 
be as high as 30% but this can be reduced with regular screening and 
appropriate therapy (8). 
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Studies have found that JIA – associated therapy should be initiated 
when the AC cell grade is >0.5+ or when fibrin is found and “keratocytic 
precipitates with corneal edema and loss of visual acuity” (5, 8).  
Current treatment frequently uses systemic immunosuppressive 
therapy and the commonest drug used is MTX. Oral corticosteroids can be 
used to gain rapid control of active uveitis(10). Corticosteroid use is not 
preferred long term due to risk of morbidity.  
Recently, biological agents have been implemented as treatment and 
most common ones are tumor necrosis factor (TNF) -alpha inhibitors, but also 
drugs that target cytokine receptors, lymphocyte antigens, and lymphocyte co- 
stimulation signals. Multiple TNF- alpha inhibitors are available, including 
infliximab and ADA which are antibodies directed against the cytokine and 
ETN acts as a decoy receptor. Infliximab is a chimeric human-mouse 
monoclonal antibody against TNF- alpha and its administered intravenously 
(11). While, ADA is a fully human monoclonal antibody against TNF- alpha 
and is subcutaneously injected (11).  
A wide range of treatment options are available since not all patients 
respond to the first line drug regimen (12). Recent advances to JIA –
associated uveitis treatment include usage of biological drugs when patients 
are resistant to systemic immunosuppressive therapy or when conventional 
therapy cannot be used.  
 
(B) Methotrexate  
 
A retrospective cohort study concluded that use of immunosuppressive 
drugs controlled inflammation and thus there was a reduced risk of vision loss 
in patients with JIA- associated uveitis (13). However, the effectiveness of 
immunosuppressive drugs to change the course of the disease is still 
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questionable. A retrospective case series found that 82% of their patients had 
a significant decrease of uveitis after a minimal 3 month period of taking MTX 
(14). However, once MTX was discontinued due to inactive uveitis 69% 
relapsed after a mean time of 7.5 months and 46% relapsed within the first 
year of withdrawal (14). However, the relapse free time was much longer in 
patients who had been on MTX for more than 3 years, children who were 8 
and older at withdrawal and those who had disease inactivity for longer than 2 
years at withdrawal – all of which should be considered when deciding to take 
a patient off of MTX (14).  
MTX use is not without risk. Sotoudehmanesh et al. found during a 
retrospective study that MTX hepatotoxicity is a common complication of long 
term use of MTX (15). The black box warnings for methotrexate include: 
hepatotoxicity, fibrosis, cirrhosis after prolonged use mainly, acute or chronic 
interstitial pneumonitis, nonproductive dry cough, diarrhea and ulcerative 
stomatitis, malignant lymphoma, tumor lysis syndrome, serious skin reactions 
and rashes and opportunistic infections (16, 17). Thus, it is important to 
prescribe MTX only when necessary and for as short a duration as possible.  
 
(C) Current therapy algorithm  
 
 A 2011 study created a therapy algorithm for active uveitis. It is 
important to note that treatment of patients with anti-inflammatory therapy is 
not curative but solely symptomatic treatment to suppress inflammation (8). If 
the patient presents with poor prognostic factors, including glaucoma, 
cataract, then they should be started on topical corticosteroids and systemic 
corticosteroids (8). However, if there are no presenting symptoms then topical 
corticosteroids will suffice. This was referred to as step one. Step two begins 
after 12 weeks or earlier if required of “topical corticosteroids use 3 times daily 
or under systemic corticosteroid dosage of more than 0.15 mg/kg body 
weight” that does not provide relief or if new uveitis develops (8). This step 
includes addition of MTX or azathioprine to topical corticosteroids. Step 3 is 
initiated after 16 weeks or earlier if required and if there is still “inactivity or 
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reactivation or new inflammation –related complications” (8). This step 
indicates the addition of ADA or infliximab or cyclosporine. (8)  
 
(D) Methotrexate + Biologics  
 
In addition to the above therapy algorithm, Henderson et al. performed 
a cross-sectional cohort study to assess the current approach in treating JIA-
caused uveitis and also idiopathic uveitis because there is no standardized 
approach (18). An analysis of patients with uveitis enrolled in the Childhood 
Arthritis and Rheumatology Research Alliance (CARRAnet) registry was 
performed and focus was given to features, diseases complications and 
medications. This was necessary to perform seeing as there is a lack of 
current standardization due to only small, retrospective case series being 
available and not randomized, controlled trials (18).  
Currently, oral and/or topical glucocorticoids, most commonly MTX, are 
the “first step in treatment of anterior, non-infectious uveitis in children” but 
long- term use should be avoided due to the side effects (18, 19). However, 
recently TNF inhibitors infliximab and ADA have been used as a treatment 
option of JIA – associated uveitis (20).  
With this information regarding current practices, examination of the 
data from CARRAnet to assess actual treatment practices of JIA- associated 
uveitis was performed. CARRAnet is a registry of over 9000 children with rare 
pediatric rheumatologic conditions and contains clinical data, prior medication 
use and disease complications.  
A total of 646 children with JIA uveitis were identified in the CARRA 
registry and the median age of disease onset was 2.8 years. 85% of patients 
received MTX (58% oral and 65% received subcutaneous); a total of 88% of 
JIA uveitis received a DMARD (18). At least one biologic agent was used in 
56% of children and 55% of the time it was a TNF inhibitor (30% ADA, 25% 
ETN, 27% infliximab, 0.5% golimumab, 0.2% certolizumab) (18). However, 
the registry did not indicate if this treatment was specific for the arthritis or 
uveitis.  
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Current guidelines state that JIA- associated uveitis should be treated 
with systemic glucocorticoids only with “severe ocular inflammation, grades 3+ 
or 4+ or impending vision loss” but the registry does not indicate the level of 
ocular inflammation or level of vision loss (18, 21). Thus, it is not possible to 
conclude if the treatment guidelines are being followed or not (18). What can 
be concluded is that MTX is used in the treatment of JIA- associated uveitis 
and TNF inhibitors are the second most common (18). 
Tappeiner et al. is a cohort study that used data from the National 
Pediatric Rheumatological Database in Germany to analyze the difference in 
treatment outcome of MTX alone, TNF inhibitors and a combination of the two 
in JIA- associated uveitis (22). 1801 patients were treated with MTX, 48 with 
TNF inhibitor monotherapy (38 with ETN, 5 with ADA and 5 with other), and 
436 were treated with a combination of MTX and a TNF inhibitor (65 with 
ADA, 9 with infliximab and 362 with ETN) (22). Risk of uveitis was significantly 
decreased in all three treatment options compared to no DMARD treatment 
(22). Also, uveitis incidence was higher in patients treated with MTX and ETN 
(5.9%) compared to those treated with MTX and ADA (1.4%) (22). As well, 
patients that were treated within the first year of JIA diagnosis with MTX had a 
significantly lower risk of developing uveitis during the follow up period (22). 
The same was not found for patients that were treated early on with TNF 
inhibitors.  
Current guidelines state starting MTX when NSAIDs and intraarticular 
corticosteroids are not sufficient and if response to MTX is insufficient or also 
in high-risk disease, addition of TNF inhibitors is recommended, particularly 
ADA due to the lower uveitis incidence compared to ETN (3, 22).  
 
(E) Biologic Agents 
 
The safety of biologics has been in question and multiple studies have 
examined the safety profile of various biologics. A source of concern while 
taking TNF- alpha inhibitors is the risk of tuberculosis reactivation. It is 
necessary to exclude existing infectious diseases and to make sure that 
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patients are up to date with immunizations prior to initiating TNF- alpha 
therapy (10).  
In 2014, a case study was presented of a two year old with JIA –
associated uveitis given ADA (23). She failed to respond to treatment with 
anti-inflammatories, low dose corticosteroids and MTX so she was placed on 
ADA, prednisone, and MTX and prednisone was tapered off after 1 month 
(23). She responded well to the new therapy with no side effects and 
displayed by good control of the disease, including resolved papilledema that 
had formed as a consequence of uveitis and was remission for 1 year (23). 
Another case involved a nine year old with an 8 year history of JIA and uveitis 
that had a relapse following two years of infliximab therapy (23). He was 
switched to ADA and MTX and he has remained in remission (23). The final 
case involved a five year old that had three flares of uveitis while on MTX 
alone (23). When ADA was added, two flares of uveitis responded well to 
local therapy but then was free of JIA and uveitis symptoms so both drugs 
were stopped and patient is in drug free remission (23). Thus supporting ADA 
therapy for uveitis in children. 
 A cross sectional retrospective analysis was performed in 2013, to 
assess ETN safety in Italian JIA patients (24). Patients given ETN after 
January 2000 were studied to assess the percentage still taking the drug 
versus those that were taken off and for what reasons. 1038 patients were 
analyzed in total, 40.7% were still taking ETN, 44.5% were discontinued and 
14.8% were lost to follow-up (24). Median therapy duration was 2.5 years. 
Clinically significant side effects were reported in 27.8% and ETN was 
discontinued due to side effects in 9.5% (24). Side effects included new onset 
or recurrent uveitis (10.2%), infections (6.6%), injection site reactions (4.4%), 
neuropsychiatric (3.1%), gastrointestinal (2.4%), hematological disorders 
(2.1%), inflammatory bowel disease (10 patients developed), malignancy (2 
patients developed) and one died of a fulminant streptococcal sepsis (24). 
However, on the other hand around half of the patients achieved complete 
disease remission under treatment with ETN (24). 41.8% to 48.6% of patients 
still taking ETN met formal criteria for inactive disease, 52.4% of patients that 
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discontinued ETN where in clinical remission and 55.8% of those lost to follow 
up where in clinical remission (24). Since ETN has a common appearance of 
new uveitis and relapse of uveitis it is not the most suitable biologic agent.  
 A prospective, comparative, multicenter cohort study found that ADA is 
more effective than infliximab at maintaining disease remission (11). 16 
children were given ADA (12 of them had JIA) and 17 children were given 
infliximab (10 of them had JIA) (11). There was no difference between the 
groups regarding time to achieve remission and time to steroid 
discontinuation. 60% of children receiving ADA were in remission at the 40 
month follow up, while 18.8% of children receiving infliximab were in 
remission at the same time (11). Also, a retrospective cohort study found that 
11/18 patients relapsed when discontinuing infliximab treatment and those 
with JIA- associated uveitis relapsed at a median time of 76 days (25). 
 A 2013 study examined to see if there would be remission and safety 
differences when giving ADA as a first anti-TNF alpha choice to one group 
and giving it as a second anti-TNF alpha drug due to loss of efficacy of 
infliximab (26). It was concluded that there’s better efficacy of ADA when it’s 
the first anti-TNF alpha drug given (26). Group 1, which has 14 children (10 of 
whom have JIA), was given ADA as first anti-TNF alpha choice and they had 
a higher probability of steroid discontinuation within 12 months and they had 
higher disease remission than group 2 (26). Group 2, which has 12 children (7 
of whom have JIA), was given ADA as a second anti- TNF alpha drug (26).  
 The U.S. Food and Drug Administration (FDA) has issued warnings 
concerning TNF alpha-blockers. FDA warns of an increased risk of infection 
of:tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, 
blastomycosis, pneumocystosis, hepatitis B, legionella, listeria and 
opportunistic infections (27). Suhler et al. performed a study of 23 patients 
being treated with infliximab for refractory uveitis (28). Some adverse events 
included pulmonary embolus, congestive heart failure, lupus like reaction in 2 
and vitreous hemorrhage is 2 patients (28).  
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(F) Adulthood 
 
 All of the aforementioned studies have described treatment during 
childhood JIA- associated uveitis. However, once the children progress into 
adulthood, disease progression, uveitis presence and complications should be 
examined. Haasnoot et al. performed a retrospective chart review of patients 
with JIA –associated chronic anterior uveitis at their 18th, 22nd and 30th year of 
life (29). The study looks into 67 patients in total that were examined during 
periods between 1974 and 2015 (29). Treatment strategies changed around 
1990 to 2000. Around 1990 MTX was initiated and in 2000 anti-TNF alpha 
agents were introduced, thus patients were split into two groups – one with 
onset of uveitis before 1990 and the other onset of uveitis after 1990 (29).  
 In regards to visual acuity, Haasnoot et al. concluded the amount of 
patients that were legally blind, had visual impairment or no visual impairment 
at 18, 22 and 30 years and then further divided them into those diagnosed 
before 1990 and those diagnosed after 1990 in both their best and worst eye 
(29). For ages 18 and 22, there was less legal blindness and visual 
impairment in those diagnosed after 1990 compared to those diagnosed 
before 1990 (29). No information was provided for those diagnosed after 1990 
at the age of 30 thus no comparison can be drawn.  
 Regarding uveitis activity, 4% of patients at 18 years old were in 
remission for the whole year (29). 54% of patients had an episode of active 
uveitis at 18 years old, 73% were on systemic immunomodulatory therapy 
(IMT) and 81% were on topical steroids (29). The majority of patients 
diagnosed after 1990 were on systemic IMT whereas 17% of those diagnosed 
before 1990 were on systemic IMT at the age of 18 and a similar percentage 
at age of 22 (29). Since uveitis is present, it’s complications also arise and 
thus a “relevant proportion of patients need cataract or glaucoma surgery 
during adulthood” (29).  
 Haasnoot et al. concluded that “introduction of MTX and anti-TNF alpha 
therapies have been important in the prevention of complications or even 
occurrence of uveitis in JIA- patients” (29). However, it is important to note the 
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effect on life that systemic IMT has. It results in more ophthalmologist visits 
and also a young woman wishing to become pregnant conflicts with its use 
(29).  
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6. Discontinuing Pharmacotherapy 
 
 Another topic of interest in JIA- associated uveitis is when therapy 
should be discontinued. As mentioned above, there are multiple side effects, 
some life threatening, for all of JIA- uveitis pharmacotherapy. General 
consensus amongst uveitis specialists is to attempt immunomodulatory 
therapy cessation after 12-24 months of disease remission (30).  
 Foell et al. performed a randomized clinical trial, in which patients were 
withdrawn from MTX at either 6 or 12 months of JIA remission (31). However, 
results did not provide clear evidence to discontinue pharmacotherapy at 6 or 
12 months. At a 24-month follow up, 56.7% of patients, that had MTX 
withdrawn at 6 months, had relapsed, while 55.6% of patients, that had MTX 
withdrawn at 12 months, had relapsed (31). The median time to relapse for 
those at 6 months was 21.0 months and 23.0 months for those at 12 months 
(31). Thus, there is little difference between discontinuing MTX treatment at 6 
months versus 12 months.  
 As detailed above, biologic agents also have serious and potentially 
fatal side effects thus they should also be discontinued when possible. 
Several studies above detail remission rates after discontinuation however 
there is not enough information regarding exactly when to discontinue other 
than uveitis specialists indicating that 12-24 months is best. Perhaps further 
scientific studies are necessary to explore this further. 
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7. Conclusion 
 
It is of upmost importance to diagnose uveitis early so as to avoid any 
and all possible complications. Regular ophthalmologic examinations with slit 
lamp are imperative in all types of JIA, however especially the ones with a 
known higher incidence of uveitis. However, it is not uncommon for diagnosis 
to be overlooked due to lack of symptoms like redness, pain or light sensitivity 
because some children are not able to sufficiently communicate or due to 
chronic disease course (32).  
Regarding safety, long term use of MTX is not advised due to its risk of 
morbidity and suppression of immune function. However, it is excellent 
regarding disease control. In regards to biologic agents, as mentioned it is 
imperative to exclude existing infectious diseases and to make sure that 
patients are up to date with immunizations prior to starting TNF alpha 
inhibitors.   
Evidence shows that early use of systemic immunosuppressants is key 
to decrease intraocular inflammation. Biologic agents have been proven to be 
beneficial as additional treatment if immunosuppressants do not provide relief. 
There is a lack of evidence to support the sole use of biologic agents. Based 
on all of the aforementioned studies, MTX should be started upon JIA 
diagnosis. Treatment with MTX is not a means of curing the disease, but 
rather it is symptomatic treatment.  If disease activity is severe or treatment is 
insufficient, biologic agents, preferably ADA, should be added.  
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